Investors, innovation and many handshakes – RESI 2018 recap
The RESI conference landed in the MaRS Discovery District on April 10 and CCAB took full advantage of the early-stage investors event.
This year, CCAB sponsored the Biotech Investors Panels, which featured sessions with entrepreneurs and investors. As CCAB broadens its focus and has started to evolve into an organization that assists with the creation and supports the growth of early-stage biotherapeutic companies in attracting investments, the sponsorship allows the organization to highlight its emerging work in this area.
Additionally, CCAB business development team members, along with CEO Robert Verhagen, held a full day of face-to-face meetings with angel investors, venture capitals, and global pharmaceutical companies to explore partnership prospects.
In the exhibit hall, the CCAB booth was a popular spot as visitors were interested in learning about CCAB’s technical offerings to help emerging companies and the research community with the launch of C-Lab. C-Lab provides customized antibody and protein production services and will soon begin to offer validated reagent antibodies from CCAB’s portfolio.
Now in its third year, the RESI Toronto event is the only one in the series that takes place outside of the U.S. and it has become a key event in the calendar for life sciences biotech investors. CCAB has participated each year, recognizing that this is an important avenue to continuing to help build a competitive life sciences ecosystem in Toronto.